52 results
6-K
EX-99.1
EVAX
Evaxion Biotech A/S
28 May 24
Evaxion Announces Business Update and First Quarter 2024 Financial Results
9:30am
year financial results were released, the Company has continued to make progress on its three-pronged business model focusing on Targets, Pipeline
6-K
EX-99.1
EVAX
Evaxion Biotech A/S
23 May 24
Current report (foreign)
5:05pm
readouts on this novel personalized cancer vaccine. With our AI-Immunology™ platform, we can precisely select vaccine targets and design personalized … select therapeutically relevant vaccine targets and generate new valuable insights. Key highlights from the Phase 2 study are:
Analyses of patient
F-1
EVAX
Evaxion Biotech A/S
6 May 24
Registration statement (foreign)
5:01pm
needs based on AI-Immunology™ identified vaccine targets. We are committed to transforming patients’ lives by providing innovative and targeted … at the date of this prospectus.
RISK FACTORS
We are a clinical-stage TechBio company with an ambition to partner on targets, pipeline and responder
6-K
EX-99.1
EVAX
Evaxion Biotech A/S
27 Mar 24
Evaxion Announces Business Update and Full Year 2023 Financial Results
8:30am
Preclinical Proof-of-Concept by H2 2024. The novel concept entails AI-identification of a new class of cancer vaccine targets, named endogenous … focusing on value realization via Targets, Pipeline and Responders based upon a muti-partner approach, we are enthusiastic about the prospects
6-K
EX-99.1
yt53syr98buh82sj et
19 Mar 24
Evaxion Hosts R&D Day and Unveils the Broad Potential of Its AI-Immunology™ Platform
8:17am
6-K
EX-99.1
4bdpabttcglit
20 Feb 24
Evaxion Announces Successful Completion of the Initial Phases of Ongoing Vaccine Collaboration with MSD
7:32am
F-1/A
e5rj016rthr14z aqdn
30 Jan 24
Registration statement (foreign) (amended)
3:16pm
6-K
EX-99.1
hljpb49lby2
24 Jan 24
Evaxion to Develop Tailored Novel Cancer Vaccines Based upon a New Untapped Source of AI-Discovered Targets
2:11pm
F-1
ublwqj58 6dio680
12 Jan 24
Registration statement (foreign)
5:17pm
6-K
EX-99.1
ysxk1lwtu5xnds3yag2c
19 Dec 23
Evaxion Announces Business Update and Third Quarter 2023 Financial Results
4:45pm
6-K
EX-99.1
107sbu
28 Nov 23
Evaxion to Unveil Potentially Groundbreaking AI-Immunology™ Precision Cancer Vaccine Concept
8:27am
6-K
EX-99.1
2kbb2ls fyf
31 Oct 23
Evaxion Announces Encouraging Initial Phase 2 Clinical Data on Its Personalized Cancer Vaccine EVX-01
11:22am
6-K
EX-99.2
gyz x5ur1k
27 Sep 23
Current report (foreign)
4:45pm
6-K
EX-99.1
r5c8i2kz mq
27 Sep 23
Current report (foreign)
4:45pm
424B4
w38zv8o
13 Sep 23
Prospectus supplement with pricing info
4:45pm
6-K
EX-99.1
4grk8e56qy y5j4zai
11 Sep 23
Current report (foreign)
8:17am
POS AM
05yxht
25 Aug 23
Prospectus update (post-effective amendment)
5:00pm
6-K/A
EX-99.1
aip1nyc8g8l2qn5u2qx
18 Aug 23
Evaxion Announces Business Update and Second Quarter 2023 Financial Results
9:28am
6-K
EX-99.2
c9yyqc6bmw327cq1b j7
17 Aug 23
Current report (foreign)
4:58pm